| Unique ID issued by UMIN | UMIN000055049 |
|---|---|
| Receipt number | R000062888 |
| Scientific Title | A systematic review of the effects of Astaxanthin on skin moisture and elasticity |
| Date of disclosure of the study information | 2024/07/23 |
| Last modified on | 2024/07/23 11:42:58 |
A systematic review of the effects of Astaxanthin on skin moisture and elasticity
A systematic review of the effects of Astaxanthin on skin moisture and elasticity
A systematic review of the effects of Astaxanthin on skin moisture and elasticity
A systematic review of the effects of Astaxanthin on skin moisture and elasticity
| Japan |
Healthy adults who were not suffering from any diseases (excluding those under 18, pregnant women, and lactating women)
| Not applicable | Adult |
Others
NO
Evaluation the effects of Astaxanthin intake on skin moisture and elasticity
Efficacy
Skin moisture content, Skin viscoelasticity
Transepidermal water loss
Others,meta-analysis etc
| 18 | years-old | <= |
| Not applicable |
Male and Female
A systematic literature search is performed through scientific and clinical trial registries databases.
The selection criteria are as follows.
Participants (P): Healthy adults (excluding those under 18, pregnant women, and lactating women, who were not suffering from any diseases).
Intervention (I): Intake of foods (tablets, capsules, granules, beverages, processed foods) containing Astaxanthin. Compositions that also contain ingredients other than Astaxanthin as test substances are excluded. Astaxanthin intake should be 0.4-30 mg/day.
Comparison (C): The comparison group is set up as consuming a placebo food that does not contain Astaxanthin.
Outcome (O): The primary outcomes are Skin moisture content as a measure of the ability to help protect skin moisture and Skin viscoelasticity as a measure of the ability to help protect skin elasticity. The secondary outcome is Transepidermal water loss as a measure of the ability to help protect skin moisture.
Study design (S): Randomized, quasi-randomized, and non-randomized controlled trials (parallel group or crossover controlled trials) will be included.
Studies which do not meet the key inclusion criteria will be excluded.
| 1st name | Shinobu |
| Middle name | |
| Last name | Seki |
FUJIFILM Corporation
Consumer Healthcare Business Div.
106-8620
26-30, Nishiazabu 2-chome, Minato-ku, Tokyo, Japan
080-1339-9052
shinobu.seki@fujifilm.com
| 1st name | Mami |
| Middle name | |
| Last name | Sawada |
FUJIFILM Corporation
Consumer Healthcare Business Div.
106-8620
26-30, Nishiazabu 2-chome, Minato-ku, Tokyo, Japan
080-8733-7808
mami.sawada.sw@fujifilm.com
FUJIFILM Corporation
None
Self funding
Yakujihou Marketing Jimusho Co., Ltd.
N/A
N/A
N/A
N/A
NO
| 2024 | Year | 07 | Month | 23 | Day |
Unpublished
Preinitiation
| 2024 | Year | 07 | Month | 23 | Day |
| 2024 | Year | 07 | Month | 24 | Day |
| 2025 | Year | 12 | Month | 31 | Day |
This research review will be conducted in accordance with PRISMA 2020.
| 2024 | Year | 07 | Month | 23 | Day |
| 2024 | Year | 07 | Month | 23 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000062888